Payment overview · 2025
General Payments
$693.22
22 reported records · 9 companies
Healthcare provider profile · identity verified
Ayman Daoud, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CANTON, MI · NPI 1073640355
Verified facts
What the public records show
CMS Open Payments records show Ayman Daoud, MD received $693.22 in general payments during 2025 across 22 reported records.
PFIZER INC. accounted for 31.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $216.41 | 31.2% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $204.23 | 29.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $106.77 | 15.4% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $42.87 | 6.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.39 | 5.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.72 | 4.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.07 | 2.8% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $18.11 | 2.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.65 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $693.22 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $204.23 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $171.11 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $106.77 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $79.16 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.11 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $45.30 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $42.87 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $40.39 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.72 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $18.11 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 115 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
115 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
132 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 529 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 405 | 91 |
| Gabapentin | Gabapentin | 303 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 278 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 273 | 57 |
| Metformin Hcl | Metformin Hcl | 272 | 50 |
| Alprazolam | Alprazolam | 270 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 254 | 28 |
| Losartan Potassium | Losartan Potassium | 247 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 221 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 208 | 44 |
| Pregabalin | Pregabalin | 207 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 33 |
| Meloxicam | Meloxicam | 183 | 29 |
| Lisinopril | Lisinopril | 169 | 33 |
| Celecoxib | Celecoxib | 167 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 151 | 37 |
| Trulicity | Dulaglutide | 132 | 26 |
| Omeprazole | Omeprazole | 120 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 120 | 30 |
| Nifedipine Er | Nifedipine | 118 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 115 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 115 | 19 |
| Allopurinol | Allopurinol | 109 | 20 |
| Furosemide | Furosemide | 102 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 20 |
| Eliquis | Apixaban | 92 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 92 | 17 |
| Buspirone Hcl | Buspirone Hcl | 87 | 12 |
| Levothyroxine Sodium | Levothyroxine Sodium | 87 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 15 |
| Ibuprofen | Ibuprofen | 77 | 13 |
| Carvedilol | Carvedilol | 65 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 11 |
| Potassium Chloride | Potassium Chloride | 64 | 14 |
| Bumetanide | Bumetanide | 63 | 16 |
| Labetalol Hcl | Labetalol Hcl | 63 | 12 |
| Trazodone Hcl | Trazodone Hcl | 63 | 11 |
| Finasteride | Finasteride | 62 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | suppressed |
| Topiramate | Topiramate | 61 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 12 |
| Famotidine | Famotidine | 57 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | suppressed |
| Clonidine | Clonidine | 49 | suppressed |
| Lorazepam | Lorazepam | 49 | suppressed |
| Prednisone | Prednisone | 47 | 37 |
| Sertraline Hcl | Sertraline Hcl | 47 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 16 |
| Farxiga | Dapagliflozin Propanediol | 41 | 11 |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 39 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 19 |
| Diazepam | Diazepam | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 16 |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Clarithromycin | Clarithromycin | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $693.22 · 22 records | PFIZER INC. | AIRSUPRA, Auvelity, Cologuard Collection Kit, KISUNLA, NURTEC ODT, PAXLOVID, QULIPTA, SMARTVEST, TRELEGY ELLIPTA, UBRELVY, YUPELRI, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error